Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-09-03), the Trailing Annual Dividend Yield of Veritas In Silico is 0.00%.
The historical rank and industry rank for Veritas In Silico's Dividend Yield % or its related term are showing as below:
TSE:130A's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.25 * Ranked among companies with meaningful Dividend Yield % only.
Veritas In Silico (TSE:130A) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Veritas In Silico Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Veritas In Silico's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:130A vs VRTX, REGN, MRNA: Dividend Yield % Comparison
For the Biotechnology subindustry, Veritas In Silico's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's Dividend Yield % falls into.
Veritas In Silico (TSE:130A) has a Dividend Yield % of 0.00% as of Sep. 03, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Veritas In Silico and its competitors. According to the industry distribution chart, Veritas In Silico ranks #999999 out of 149 companies in the Biotechnology industry.
Is Veritas In Silico's Dividend Yield % too high?
Veritas In Silico's current Dividend Yield % is 0.00%. Based on the distribution chart, Veritas In Silico ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #999999 out of 149 companies for Dividend Yield %. This places Veritas In Silico in the lower half of its industry. The industry median Dividend Yield % is 1.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.25, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Veritas In Silico and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円266.78, compared to a current price of 円433.00 — trading 62.3% above its estimated fair value. The current Dividend Yield % is 0.00%. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Dividend Yield % is 0.00% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veritas In Silico (TSE:130A) Overvalued in 2026?
Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued.
The current stock price of 円433.00 is trading 62.3% above its estimated GF Value™ of 円266.78.
GuruFocus considers Veritas In Silico to be Significantly Overvalued.
Key valuation signals for TSE:130A:
Dividend Yield %: 0.00%
GF Value™: 円266.78 vs. price of 円433.00 (62.3% above fair value)
No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score
Get the complete analysis for TSE:130A
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
